This template is based on the NHS ‘Clinical guide for the management of acute diabetes during the coronavirus pandemic’ ref 001559. The body of the document has been retained but space has been provided for you to populate to describe your local arrangements. In addition to the ‘blank’ template we have provided a specimen example which may be helpful. Clearly, arrangements will be different for different services and will depend on staff levels.  
We hope you will find this useful in planning diabetes services in the light of the existing NHS guidance.     

The aim of this document is to provide some detail on how maintenance of a level of specialist diabetes service can be achieved during COVID-19

Updated November 2020

Media Release from Diabetes UK

Does Liraglutide therapy affect the metabolic response in patients with elevated alanine aminotransferase and type 2 diabetes mellitus?

Piya Sen Gupta¹, ABCD Research Fellow KY Thong¹, M Cull¹, P Winocour², REJ Ryder¹ on behalf of the ABCD nationwide liraglutide audit contributors

¹City Hospital, Birmingham, UK

²QE 2 Hospital, Welwyn Garden City, UK

Differences in response between exenatide and liraglutide in the Association of British Clinical Diabetologists (ABCD) nationwide audits

R.E.J. Ryder¹, K.Y. Thong¹, M.L. Cull¹, A.P. Mills¹, C. Walton² on behalf of ABCD nationwide exenatide and liraglutide audits contributors

¹City Hospital, Diabetes, Birmingham, UK

²Hull Royal Infirmary, Diabetes, Hull, UK

ABCD Nationwide Exenatide and Liraglutide Audits

REJ Ryder¹ and S Gough² on behalf of the ABCD nationwide exenatide and liraglutide audit contributors

¹City Hospital, Birmingham, UK

²Oxford, UK

ABCD Nationwide Exenatide and Liraglutide Audits

Dr Bob Ryder¹ and Professor Stephen Gough² on behalf of the ABCD nationwide exenatide and liraglutide audit contributors

¹City Hospital, Birmingham, UK

²Oxford, UK